Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + fluorouracil + leucovorin + bevacizumab (University of Texas MD Anderson Cancer Center)
- Development stage
- Phase 4
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
This combination therapy regimen, developed and evaluated by the M.D. Anderson Cancer Center, involves the administration of oxaliplatin via hepatic arterial infusion (HAI) in conjunction with systemic intravenous fluorouracil (5-FU), leucovorin, and bevacizumab (Avastin). The regimen is specifically designed for patients with advanced solid tumors that have metastasized to the liver. Oxaliplatin, a platinum-based small molecule, functions by forming DNA cross-links, thereby inhibiting DNA replication and transcription. Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, a key enzyme in DNA synthesis, while leucovorin is administered to enhance the binding and inhibitory effect of 5-FU on its target. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis. The use of HAI for oxaliplatin delivery aims to achieve high local drug concentrations within the liver while minimizing systemic side effects.
- Other names
- HAI oxaliplatin + systemic 5-FU/LV/BevacizumabHepatic Arterial Infusion of Oxaliplatin + 5-FU/Leucovorin/Avastin
02
Targets
Beyond the preview
Go deeper on oxaliplatin + fluorouracil + leucovorin + bevacizumab (University of Texas MD Anderson Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + fluorouracil + leucovorin + bevacizumab (University of Texas MD Anderson Cancer Center).